SecBot SecBot
PRESS-RELEASE ·Filed May 7, 2026

CLDX

Celldex Therapeutics, Inc.
MIXED
Impact 6/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

Traders should watch for topline Phase 3 barzolvolimab CSU data in Q4 2026 and Phase 2 PN/AD readouts in mid-to-late 2026 as key catalysts. The $345M financing removes near-term dilution risk, but escalating R&D spend and lack of revenue mean the stock will trade primarily on pipeline execution.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$33.97
T+0 close · May 7, 2026 · via day close
Latest settled
+14.95%
T+60 · $39.05
Vs SPY
+10.11%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 8 $33.97entry
  2. T+1 · 6mo ago −4.97%α −5.21% · $32.28
  3. T+5 · 6mo ago −4.47%α −5.94% · $32.45
  4. T+20 · 5mo ago −15.75%α −15.77% · $28.62
  5. T+60 · 3mo ago +14.95%α +10.11% · $39.05
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Celldex reported Q1 2026 EPS of -$1.18 (miss vs -$1.13 consensus) and revenue of $15K (miss vs $861K), reflecting widening losses as the company invests heavily in its pipeline. Positively, the company completed enrollment six months ahead of schedule in its Phase 3 barzolvolimab CSU studies, with topline data expected in Q4 2026 and a BLA submission planned for 2027, and strengthened its balance sheet with a $345M public offering in April. The mixed report balances near-term financial deterioration against significant pipeline progress and a cash runway through 2028.

Key Financial Metrics

EPS
−$1.18
est −$1.13 · -4.4%
Revenue
$15.0K
est $861.0K · -98.3% · -97.8% YoY
Rating
miss

Key Facts

  • EPS of -$1.18 vs consensus -$1.13 (miss of -4.4%)
  • Revenue of $15K vs consensus $861K (miss, but pre-revenue biotech)
  • Net loss widened to $78.7M from $53.8M in Q1 2025
  • Enrollment completed six months ahead of guidance in Phase 3 CSU studies (EMBARQ-CSU1 and 2, n=1,939 patients)
  • Topline Phase 3 CSU data expected Q4 2026; BLA filing planned for 2027
  • Raised $345M in gross proceeds from a follow-on public offering in April 2026
  • Cash, cash equivalents and marketable securities $451.5M at March 31, 2026
  • Cash used in operating activities $65.6M in Q1 2026
  • Phase 2 PN and AD studies fully enrolled; topline data expected summer/late 2026
  • Phase 1 CDX-622 asthma proof-of-mechanism study ongoing

Financial Impact

Net loss of $78.7M in Q1 2026, compared to $53.8M in Q1 2025; cash balance of $451.5M supplemented by $345M offering, extending runway through 2028

revenueepsnet losscash positiondilution

Risk Factors

  • Clinical trial failure or negative data in upcoming readouts
  • Dilution from the April 2026 public offering (11.9M shares issued)
  • Continued operating losses and cash burn ($65.6M operating cash flow in Q1)
  • Competition from other chronic urticaria therapies
  • Regulatory delays or setbacks for BLA submission

Market Snapshot

Exchange
Nasdaq
Sector
In Vitro & In Vivo Diagnostic Substances
Analyst Consensus
91% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3290499

Track record

21 reports on CLDX

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +19.96% at T+20 after the Jun 14, 2026 report. 4 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.97 Now $28.59 −1.31% settles Feb 12
  2. Nov 5, 202611d ago S-3ASR Neutral 3/10 Entry $29.87 Now $28.59 −4.29% settles Feb 4
  3. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $29.87 Now $28.59 −4.29% settles Feb 4
  4. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $29.71 Now $28.59 −3.77% settles Feb 1
  5. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $30.43 Now $28.59 −6.05% settles Jan 4
  6. Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
  7. Sep 22, 20267w ago 8-K Bullish 7/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
  8. Sep 22, 20267w ago Press Release Bullish 7/10 Entry $33.51 Now $28.59 −14.68% settles Dec 16
  9. Jun 14, 202622w ago Press Release Bearish 6/10 Entry $32.12 to $38.10 Now $28.59 +10.99% ▼ −18.62% −18.22% vs SPY
  10. Jun 14, 202622w ago Press Release Bullish 7/10 Entry $32.12 to $38.10 Now $28.59 −10.99% ▲ +18.62% +18.22% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (11h 50m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026